Quinazoline derivatives used to treat HIV
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F21%3A00552130" target="_blank" >RIV/61388963:_____/21:00552130 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/patent/search/family/055305044/publication/KR102288855B1?q=KR2288855" target="_blank" >https://worldwide.espacenet.com/patent/search/family/055305044/publication/KR102288855B1?q=KR2288855</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
korejština
Original language name
HIV를 치료하는데 사용되는 퀴나졸린 유도체
Original language description
화학식 I의 화합물 및 그의 호변이성질체 및 제약 염, 이러한 화합물을 함유하는 조성물 및 제제, 및 이러한 화합물을 사용 및 제조하는 방법이 본원에 기재된다. <화학식 I>
Czech name
—
Czech description
—
Classification
Type
P - Patent
CEP classification
—
OECD FORD branch
10401 - Organic chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Patent/design ID
KR102288855
Publisher
KR001 -
Publisher name
Korean Intellectual Property Office (KIPO)
Place of publication
Daejeon Metropolitan City
Publication country
KR - KOREA, REPUBLIC OF
Date of acceptance
Aug 11, 2021
Owner name
Gilead Sciences, Inc. - Ústav organické chemie a biochemie AV ČR, v. v. i
Method of use
B - Výsledek je využíván orgány státní nebo veřejné správy
Usage type
A - K využití výsledku jiným subjektem je vždy nutné nabytí licence